Therapy of pericarditis with colchicine, interleukin-1 antagonists, immunosuppressants

Abstract

Eight years have passed since the update of the European Guidelines for the management of pericarditis, almost 3 years of which the pandemic of the new coronavirus has been continuing. COVID-19 has changed the structure and the course of all cardiac diseases. At present there is no doubt that the dominant cause of pericarditis is the new coronavirus SARS-CоV-2. However, such non-infectious causes as systemic inflammatory diseases, paraneoplastic and postpericardiotomy syndromes that require a differentiated therapeutic strategy, remain relevant. This part of the systematic review addresses the treatment of incessant, recurrent, and chronic viral/idiopathic pericarditis. Particular attention is paid to publications on the effectiveness of the therapy with colchicine and interleukin-1 antagonists. The review of the medical resources such as PubMed, Google Scholar, UpToDate (publications from 01.1990 to 10.2022) was conducted, the issues of differentiated pericarditis therapy with various anti-inflammatory drugs were studied thoroughly.